Comparative Study of Triglyceride Level in Ischemic Heart Disease Patients in different age groups of Patients in south east Rajasthan
Backgrounds: Elevated body triglycerides have been implicated as a risk factor of ischemic heart disease (IHD).
Objectives: To study the association of serum triglyceride with ischemic heart disease and to assess the relationship of serum triglyceride with other established conventional risk factors.
Methods: A cross sectional case-control study of 75 cases of IHD and 75 controls without having any evidence of IHD/CHD between age group 30-70 years. Serum triglyceride levels were estimated by using Colorimetric Method and other risk factors by enzymatic methods.
Results: Mean serum triglyceride (263.674 ± 89.029mg/dl) was significantly higher in cases than controls (98.833 ± 62.682mg/dl). Amongst the patients of IHD, significantly higher level of Serum triglyceride was found in diabetics (340.63±90.78mg/dl) than non-diabetics (225.19±58.30mg/dl), male elderly (>60years of age) smokers (304.20±88.60mg/dl) compared to non smoker (206.37±48.88mg/dl), elderly male with high (>150mg/dl) LDL (323.48±86.73mg/dl) compared to patients with normal (<150mg/dl) LDL (249.33±66.12 mg/dl). Similarly male patients of IHD with high (>40mg/dl) VLDL had significantly higher serum triglyceride (326.49±77.95mg/dl) compared to male patients with normal (<40mg/dl) VLDL (257.18±85.46mg/dl).
Conclusion: High serum triglyceride level (>200mg/dl) may provide a cost effective tool for predicting an impending ischemic heart disease especially in diabetic patients, male elderly smokers, elderly males with high LDL, male patients of ischemic heart disease with high VLDL level.
2. Chockalingam A, Balagner-vintro I: Impending Global Pandemic of cardiovascular diseases; challanges and opportunities for the prevention and control of cardiovascular diseases in developing countries and economics in transition Barcelona, Prous Science, 1999.
3. Shepherd J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med. 1995; 333:1301-7.
4. Schonfeld G. Inherited disorders of lipid transport. Endocrinol Metab Clin North Am. 1990; 19:229–57.
5. Jacobs DR, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride: the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1982; 116:878–85. [PubMed: 7148814]
6. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007; 115:450–8. [PubMed: 17190864]
7. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3(2):213–9. [PubMed: 8836866]
8. Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004; 110:2678–86. [PubMed: 15492305]
9. Di Angelantonio E, Sarwar N, Perry P, et al. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins and risk of vascular disease. JAMA. 2009; 302:1993–2000. [PubMed: 19903920]
10. Carey VJ, Bishop L, Laranjo N, et al. Contribution of High Plasma Triglycerides and Low High Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control. Am J Cardiol. 2010; 106:757–63. [PubMed: 20816113]
11. Assmann G, Cullen P, Schulte H. Non-LDL-related dyslipidaemia and coronary risk: a case– control study. Diab Vasc Dis Res. 2010; 7(3):204–12. [PubMed: 20643700]
12. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002; 105:1424–8. [PubMed: 11914249] Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51:724–30. [PubMed: 18279736]
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002; 106(25):3143–421. [PubMed: 12485966]
14. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb.1991; 11:2-14.
15. Garber AM, Avins AL. Triglyceride concentration and coronary heart disease [editorial; comment] [see comments]. BMJ. 1994;309:2–3.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
Rights of Authors:
The International Journal of Drug Regulatory affairs. recognize the retention of the following:
- Patent and trademark rights and rights to any process or procedure described in the article.
- The right to photocopy or make single electronic copies of the article for their own personal use, including for their own classroom use, or for the personal use of colleagues, provided the copies are not offered for sale and are not distributed in a systematic way outside of their employing institution (e.g. via an e-mail list or public file server). Posting of an article on a secure network (not accessible to the public) within the author’s institution is permitted.
- The right, subsequent to publication, to use the article or any part thereof free of charge in a printed compilation of works of their own, such as collected writings or lecture notes.
Note: All copies, paper, electronic or other use, of the information must include an indication of the IJDRA copyright and a full citation of the journal source.
- If the article was prepared jointly with other author(s), the signing author has informed the co-author(s) of the terms of this copyright transfer and is signing on their behalf as their agent and represents that he or she is authorized to do so, then please confirm by checking the appropriate box following the signature line. The signing author shall bear the responsibility for designating the co-author(s) and must inform the IJDRA of any changes in authorship.
- If copyright is held by the employer, then the employer or an authorized representative of the employer must sign. If the author signs, it is understood that this is with the authorization of the employer and the employer’s acceptance of the terms of the transfer.
The author(s) warrant(s) that the article is the author’s original work and has not been published before. The author(s) warrant(s) that the article contains no libelous or other unlawful statements, and does not infringe on the rights of others. If excerpts from copyrighted works are included, the author(s) has (have) obtained or will obtain written permission from the copyright owners and will credit the source in the article.
Preprints: The author(s) must agree that if a prior version of this work (normally a preprint) has been posted to an electronic public server, they will not update and/or replace the prior version in order to make it identical in content to the final published version.